With the way TODOS has set the products up as solutions to testing, preventing, and treating Covid we are in a great position to capture a significant market share going forward. Not withstanding many other diverse aspects of the company e.g. Monkey Pox ... TODOS looks very attractive.. Emergency usage of Tollovir with potential blockbuster efficacy data for both hospitalized and Long Covid sufferers puts us front and center of the full spectrum of investors. Look what Ivermectin did w/o any real research and marketing for Covid specifically--just word of mouth. This is the right time and place to be in the long-term battle against this virus. 3CLP and Anti-cytochrome is currently state of the art and we are in the thick of it. Pray for emergency usage approval-- the products will do the rest.

Cheers,
Doc